CalPERS Committee Will Not Call for GlaxoSmithKline to Report Licensing of Antiretroviral Drugs
December 17, 2003
The California Public Employees Retirement System's investment committee on Monday decided 6-5 not to send a "stern" letter to pharmaceutical company GlaxoSmithKline requesting that the drug maker submit a report on its licensing of antiretroviral drugs, Reuters reports (Reuters, 12/15). CalPERS, the largest U.S. pension fund, is believed to hold roughly $760 million shares of GSK, which manufactures several antiretroviral drugs (Kaiser Daily HIV/AIDS Report, 8/25). The letter also would have asked CalPERS to discuss a ruling by South Africa's Competition Commission about GSK's pricing of antiretrovirals, Reuters reports (Reuters, 12/15). South Africa's Competition Commission in October decided that GSK and Boehringer Ingelheim violated the country's competition act by setting antiretroviral drug prices too high and by refusing to license their patents to generic drug manufacturers. The commission recommended to the Competition Tribunal -- which has enforcement powers -- that the two companies be forced to allow generic licenses in exchange for royalties and be required to pay a fine of 10% of their annual antiretroviral sales for each year that they have violated the 1998 law. Both companies denied the commission's charges that they violated the country's competition act; however, the two companies last week signed a deal in which they will grant licenses to four different generic drug makers to manufacture their patented antiretroviral drugs. The commission said that following the announcement of the deal, it would ask that GSK not be fined, and the commission said that it is negotiating a similar deal with Boehringer (Kaiser Daily HIV/AIDS Report, 12/11).
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.